Human Vaccines & Immunotherapeutics最新文献_第10页

Penta- and hexavalent vaccination of extremely and very-to-moderate preterm infants born at less than 34 weeks and/or under 1500 g: A systematic literature review. 34周以下和/或1500克以下出生的极重度和极中度早产儿的五价和六价疫苗接种：一项系统文献综述。

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2023-12-31 DOI: 10.1080/21645515.2023.2191575

Markus Knuf, Marie-Laure Charkaluk, Phung Nguyen The Nguyen, Ignacio Salamanca de la Cueva, Petra Köbrunner, Lauren Mason, Maurine Duchenne, Valérie Berlaimont

{"title":"Penta- and hexavalent vaccination of extremely and very-to-moderate preterm infants born at less than 34 weeks and/or under 1500 g: A systematic literature review.","authors":"Markus Knuf, Marie-Laure Charkaluk, Phung Nguyen The Nguyen, Ignacio Salamanca de la Cueva, Petra Köbrunner, Lauren Mason, Maurine Duchenne, Valérie Berlaimont","doi":"10.1080/21645515.2023.2191575","DOIUrl":"10.1080/21645515.2023.2191575","url":null,"abstract":"Debate regarding vaccinating high-risk infants with penta- and hexavalent vaccines persists, despite their good immunogenicity and acceptable safety profile in healthy full-term infants. We report the findings of a systematic literature search that aimed to present data on the immunogenicity, efficacy, effectiveness, safety, impact, compliance and completion of penta- and hexavalent vaccination in high-risk infants, including premature newborns. Data from the 14 studies included in the review showed that the immunogenicity and the safety profile of penta- and hexavalent vaccines in preterm infants was generally similar to those seen in full-term infants, with the exception of an increase in cardiorespiratory adverse events such as apnea, bradycardia and desaturation following vaccination in preterm infants. Despite recommendations of vaccinating preterm infants according to their actual age, and the relatively high completion rate of the primary immunization schedule, vaccination was often delayed, increasing the vulnerability of this high-risk population to vaccine-preventable diseases.","PeriodicalId":13058,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"19 1","pages":"2191575"},"PeriodicalIF":4.8,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/09/b3/KHVI_19_2191575.PMC10120554.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9930496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review. 与Delta和其他变体相比，预Omicron COVID-19疫苗在减少感染、住院、严重程度和死亡率方面的有效性:一项系统综述。

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2023-12-31 Epub Date: 2023-03-13 DOI: 10.1080/21645515.2023.2167410

Pradipta Paul, Ahmed El-Naas, Omar Hamad, Mohammad A Salameh, Nada Mhaimeed, Ibrahim Laswi, Ali A Abdelati, Jamal AlAnni, Bushra Khanjar, Dana Al-Ali, Krishnadev V Pillai, Abdallah Elshafeey, Hasan Alroobi, Zain Burney, Omar Mhaimeed, Mohammad Bhatti, Pratyaksha Sinha, Muna Almasri, Ahmed Aly, Khalifa Bshesh, Reem Chamseddine, Omar Khalil, Ashton D'Souza, Thanu Shree, Narjis Mhaimeed, Lina Yagan, Dalia Zakaria

{"title":"Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review.","authors":"Pradipta Paul, Ahmed El-Naas, Omar Hamad, Mohammad A Salameh, Nada Mhaimeed, Ibrahim Laswi, Ali A Abdelati, Jamal AlAnni, Bushra Khanjar, Dana Al-Ali, Krishnadev V Pillai, Abdallah Elshafeey, Hasan Alroobi, Zain Burney, Omar Mhaimeed, Mohammad Bhatti, Pratyaksha Sinha, Muna Almasri, Ahmed Aly, Khalifa Bshesh, Reem Chamseddine, Omar Khalil, Ashton D'Souza, Thanu Shree, Narjis Mhaimeed, Lina Yagan, Dalia Zakaria","doi":"10.1080/21645515.2023.2167410","DOIUrl":"10.1080/21645515.2023.2167410","url":null,"abstract":"Despite widespread mass rollout programs, the rapid spread of the SARS-CoV-2 Omicron variant called into question the effectiveness of the existing vaccines against infection, hospitalization, severity, and mortality compared to previous variants. This systematic review summarizes and compares the effectiveness of the COVID-19 vaccines, with respect to the above outcomes in adults, children, and adolescents. A comprehensive literature search was undertaken on several databases. Only 51 studies met our inclusion criteria, revealing that the protection from primary vaccination against Omicron infection is inferior to protection against Delta and Alpha infections and wanes faster over time. However, mRNA vaccine boosters were reported to reestablish effectiveness, although to a lower extent against Omicron. Nonetheless, primary vaccination was shown to preserve strong protection against Omicron-associated hospitalization, severity, and death, even months after last dose. However, boosters provide more robust and longer-lasting protection against hospitalizations due to Omicron as compared to only primary series.","PeriodicalId":13058,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"19 1","pages":"2167410"},"PeriodicalIF":4.8,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ec/3b/KHVI_19_2167410.PMC10054360.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9210285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preclinical safety evaluation of a bivalent inactivated EV71-CA16 vaccine in mice immunized intradermally. 皮内免疫小鼠双价灭活疫苗EV71-CA16的临床前安全性评价

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2023-12-31 DOI: 10.1080/21645515.2023.2209472

Yun Liao, Qinfang Jiang, Xinqian Huo, Li Yu, Jinling Yang, Heng Zhao, Dandan Li, Xingli Xu, Guorun Jiang, Caixing Zhang, Cong Li, Yun Li, Ying Zhang, Mingxiang Shao, Baofeng Liu, Lianzhong Shen, Shengtao Fan, Qihan Li

{"title":"Preclinical safety evaluation of a bivalent inactivated EV71-CA16 vaccine in mice immunized intradermally.","authors":"Yun Liao, Qinfang Jiang, Xinqian Huo, Li Yu, Jinling Yang, Heng Zhao, Dandan Li, Xingli Xu, Guorun Jiang, Caixing Zhang, Cong Li, Yun Li, Ying Zhang, Mingxiang Shao, Baofeng Liu, Lianzhong Shen, Shengtao Fan, Qihan Li","doi":"10.1080/21645515.2023.2209472","DOIUrl":"10.1080/21645515.2023.2209472","url":null,"abstract":"Hand, foot and mouth disease is a common acute viral infectious disease that poses a serious threat to the life and health of young children. With the development of an effective inactivated EV71 vaccine, CA16 has become the main pathogen causing HFMD. Effective and safe vaccines against this disease are urgently needed. In our previous study, a bivalent inactivated vaccine was shown to have good immunogenicity and to induce neutralizing antibodies in mice and monkeys. Repeated administration toxicity is a critical safety test in the preclinical evaluation of vaccines. In this study, BALB/c mice were used to evaluate the toxicity of the bivalent vaccine after multiple intradermal administrations. Clinical observation was performed daily, and body weight, food intake, hematological characteristics, serum biochemical parameters, antinuclear antibodies, CD4+/CD8a+ T-cell proportions, bone marrow smear results and pathology results were recorded. The results showed that there was no significant change at the injection site and no adverse reactions related to the vaccine. The bivalent inactivated EV71-CA16 vaccine exhibits good safety in mice, and these results provide a sufficient basis for further clinical trials.","PeriodicalId":13058,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"19 1","pages":"2209472"},"PeriodicalIF":4.8,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7b/fb/KHVI_19_2209472.PMC10208166.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9514112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of rotavirus vaccine introduction in Abidjan, Côte d'Ivoire. 在阿比让引入轮状病毒疫苗的影响Côte科特迪瓦。

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2023-12-31 Epub Date: 2023-01-31 DOI: 10.1080/21645515.2022.2156231

Alice Britoh Mlan, Rachel M Burke, Hamidou Koné, Catherine Boni-Cisse, Rebecca N'Guessan, Flore Zaba, Lepri Nicaise Aka, Kofi N'Zue, San Koffi Adom, Sié Kabran Kouadio, Armel Bhérat Kouadio, Syndou Meité, Stephane Koffi, Hortense Faye-Kette, Keith Shaba, Bernard Ntsama, Joseph Biey, Negar Aliabadi, Jason M Mwenda, Umesh D Parashar, Jacqueline E Tate

{"title":"Impact of rotavirus vaccine introduction in Abidjan, Côte d'Ivoire.","authors":"Alice Britoh Mlan, Rachel M Burke, Hamidou Koné, Catherine Boni-Cisse, Rebecca N'Guessan, Flore Zaba, Lepri Nicaise Aka, Kofi N'Zue, San Koffi Adom, Sié Kabran Kouadio, Armel Bhérat Kouadio, Syndou Meité, Stephane Koffi, Hortense Faye-Kette, Keith Shaba, Bernard Ntsama, Joseph Biey, Negar Aliabadi, Jason M Mwenda, Umesh D Parashar, Jacqueline E Tate","doi":"10.1080/21645515.2022.2156231","DOIUrl":"10.1080/21645515.2022.2156231","url":null,"abstract":"Côte d'Ivoire introduced rotavirus vaccine in March 2017. Rotavirus surveillance is conducted at Centre Hospitalier Universitaire de Yopougon in Abidjan, the capital city. Children <5 years of age are enrolled in rotavirus surveillance if admitted to the hospital with acute gastroenteritis. We used sentinel surveillance data from 2014 through mid-2019 to compare trends in rotavirus pediatric gastroenteritis hospitalizations before and after rotavirus vaccine introduction. We used Poisson regression to analyze changes in rotavirus prevalence, adjusting for calendar month and accounting for total monthly admissions; January 2014 - December 2016 was considered \"pre-vaccine,\" and January 2017 - June 2019 was considered \"post-vaccine.\" Age distribution and severity were compared between periods using the Mann-Whitney U test. Rotavirus-positive admissions declined 51% (95% CI: 28%-67%), from 31.5% pre-vaccine to 14.9% afterward. The median age of rotavirus-positive children increased from 7 months (interquartile range [IQR]: 5-11) in the pre-vaccine period to 11 months (IQR: 7-18, p = .005) in the post-vaccine period. The median severity score decreased from 11 to 9 (p = .008) among all children, and from 12 pre- to 10.5 post-vaccine (p = .35) among rotavirus-positive children. Our findings suggest that rotavirus vaccine introduction contributed to reduced rotavirus hospitalization in Abidjan and possibly more broadly.","PeriodicalId":13058,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"19 1","pages":"2156231"},"PeriodicalIF":4.8,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980462/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9110567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-lasting complete response to SHR-1701 plus famitinib in refractory advanced gallbladder cancer: A case report SHR-1701 加法米替尼治疗难治性晚期胆囊癌的持久完全反应：病例报告

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2023-12-21 DOI: 10.1080/21645515.2023.2294575

Lixia Yi, Xiaoyan Zhu, Jing Xie, Zhiqiang Meng

引用次数: 0

Evaluating the accessibility and capacity of SARS-CoV-2 vaccination and analyzing convenience-related factors during the Omicron variant epidemic in Beijing, China 在中国北京 Omicron 变种疫情期间评估 SARS-CoV-2 疫苗接种的可及性和能力，并分析与便利性相关的因素

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2023-12-19 DOI: 10.1080/21645515.2023.2289250

Yuping Duan, Mingyue Jiang, Luodan Suo, Mingyu Xu, Xiaomei Li, Qing Wang, Chengxu Bai, Jiang Wu, Zheng Xu, Weizhong Yang, Luzhao Feng, Juan Li

引用次数: 0

A bibliometric and knowledge-map study of CAR-T cell-related cytokine release syndrome (CRS) from 2012 to 2023 2012年至2023年CAR-T细胞相关细胞因子释放综合征（CRS）的文献计量和知识图谱研究

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2023-12-19 DOI: 10.1080/21645515.2023.2291900

Huimin Li, Qing Huang, Yuan Zhang

引用次数: 0

Potential motivators affecting parental intention in COVID-19 vaccination for children aged 6 months to 4 years: Implications for targeted vaccine interventions in Japan 影响家长为 6 个月至 4 岁儿童接种 COVID-19 疫苗意向的潜在动机：对日本有针对性的疫苗干预措施的影响

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2023-12-19 DOI: 10.1080/21645515.2023.2296737

Yukiko Kato, Tomohiro Shinozaki, Daisuke Sugiyama, Atsuko Taguchi, Satoko Nagata

引用次数: 0

Comparing the immune response and protective effect of COVID-19 vaccine under different vaccination strategies 比较不同接种策略下 COVID-19 疫苗的免疫反应和保护效果

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2023-12-19 DOI: 10.1080/21645515.2023.2273155

Tianyi Zhao, Xiaoping Huang, Yuelong Shu

引用次数: 0

Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials 在 18 岁或 18 岁以上的中国参与者中接种 SARS-CoV-2 mRNA 疫苗 (SYS6006) 的安全性和免疫原性：两项随机、观察者盲法、安慰剂对照和剂量递增的 1 期临床试验

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2023-12-18 DOI: 10.1080/21645515.2023.2285089

Gui-Ling Chen, Yuan-Zheng Qiu, Kai-Qi Wu, Ying Wu, Yuan-Hui Wang, Yu-Ying Zou, Cong-Gao Peng, Jie Zhao, Chang Su, Jun-Heng Ma, Shao-Nan Ni, Xing Wang, Ting-Han Jin, Qi Jiang, Tong Guo, Yan Xu, Chao-Chao Huang, Qing Zhang, Kai-Li Liu, Li Ji, Han-Yu Yang, Chun-Lei Li, Yu-Wen Su, Xiang Lu, Lan-Juan Li

引用次数: 0